Pliant Therapeutics, Inc. PLRX

PLRX Company Overview

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for fibrotic diseases and certain forms of cancer through targeting integrins, which are cell-surface proteins involved in tissue remodeling, fibrosis, and tumor progression. The company operates within the biotechnology and biopharmaceutical industries, with its primary revenue sources historically consisting of collaboration agreements and financing activities rather than commercial product sales, as it has not yet commercialized an approved therapy. Pliant’s lead programs have focused on idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and oncology-related indications involving fibrosis-associated pathways.

The company’s strategy centers on precision-designed small molecule integrin inhibitors intended to selectively block disease-driving mechanisms while limiting off-target effects. Pliant was founded in 2015 and is headquartered in South San Francisco, California. Since its formation, the company has expanded its pipeline through internal discovery efforts and platform-based drug development, advancing multiple candidates into clinical development. Public filings and investor materials identify integrin biology expertise and fibrosis-focused specialization as central competitive differentiators.